Older adults achieved a lower immune response than hoped for in an early trial of Sanofi (Euronext: SAN) and GlaxoSmithKline’s (LSE: GSK) coronavirus vaccine.
While the firms say they retain confidence in the capacity of the adjuvanted recombinant platform to deliver an effective vaccine for all adults, the setback will mean a delay to the program.
GSK and Sanofi now plan a Phase IIb study for early 2021, including a proposed comparison with an authorized COVID-19 vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze